carbamates has been researched along with Brain Neoplasms in 12 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 8.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "A multicenter, retrospective case series investigation of consecutive BRAF-mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response." | 7.96 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. ( Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H, 2020) |
| "Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy." | 5.62 | Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. ( Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP, 2021) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 5.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 4.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "A multicenter, retrospective case series investigation of consecutive BRAF-mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response." | 3.96 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. ( Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H, 2020) |
| "Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy." | 1.62 | Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. ( Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP, 2021) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 1.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y | 1 |
| Zhang, C | 1 |
| He, L | 1 |
| Song, X | 1 |
| Zheng, C | 1 |
| Pan, Y | 1 |
| Yu, S | 1 |
| Holbrook, K | 1 |
| Lutzky, J | 1 |
| Davies, MA | 1 |
| Davis, JM | 1 |
| Glitza, IC | 1 |
| Amaria, RN | 1 |
| Diab, A | 1 |
| Patel, SP | 1 |
| Amin, A | 1 |
| Tawbi, H | 1 |
| McLoughlin, EM | 1 |
| Fadul, CE | 1 |
| Patel, SH | 1 |
| Hall, RD | 1 |
| Gentzler, RD | 1 |
| Li, AS | 1 |
| Leng, T | 1 |
| Nagpal, S | 1 |
| Liao, YJ | 1 |
| Khullar, K | 1 |
| Hanft, S | 1 |
| Mehnert, JM | 1 |
| Weiner, JP | 1 |
| Khasabova, IA | 1 |
| Holman, M | 1 |
| Morse, T | 1 |
| Burlakova, N | 1 |
| Coicou, L | 1 |
| Harding-Rose, C | 1 |
| Simone, DA | 1 |
| Seybold, VS | 1 |
| Winkler, K | 1 |
| Ramer, R | 1 |
| Dithmer, S | 1 |
| Ivanov, I | 1 |
| Merkord, J | 1 |
| Hinz, B | 1 |
| Dorneburg, C | 1 |
| Goß, AV | 1 |
| Fischer, M | 1 |
| Roels, F | 1 |
| Barth, TF | 1 |
| Berthold, F | 1 |
| Kappler, R | 1 |
| Oswald, F | 1 |
| Siveke, JT | 1 |
| Molenaar, JJ | 1 |
| Debatin, KM | 1 |
| Beltinger, C | 1 |
| Cenciarelli, C | 1 |
| Marei, HE | 1 |
| Zonfrillo, M | 1 |
| Casalbore, P | 1 |
| Felsani, A | 1 |
| Giannetti, S | 1 |
| Trevisi, G | 1 |
| Althani, A | 1 |
| Mangiola, A | 1 |
| Kunschner, LJ | 1 |
| Fine, H | 1 |
| Hess, K | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Paylor, B | 1 |
| Holt, S | 1 |
| Fowler, CJ | 1 |
| Linfoot, PA | 1 |
| Gray, JW | 1 |
| Dean, PN | 1 |
| Marton, LJ | 1 |
| Deen, DF | 1 |
1 trial available for carbamates and Brain Neoplasms
| Article | Year |
|---|---|
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glio | 2002 |
11 other studies available for carbamates and Brain Neoplasms
| Article | Year |
|---|---|
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; | 2020 |
Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain | 2019 |
Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib.
Topics: Antineoplastic Agents; Astrocytoma; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; MAP | 2020 |
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; F | 2021 |
Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
Topics: Animals; Arachidonic Acids; Benzamides; Brain Neoplasms; Cannabinoid Receptor Antagonists; Carbamate | 2013 |
Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells.
Topics: Aged; Amidohydrolases; Animals; Apoptosis; Arachidonic Acids; Benzamides; Biomarkers, Tumor; Brain N | 2016 |
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Topics: Amyloid Precursor Protein Secretases; Animals; Apoptosis; Brain Neoplasms; Carbamates; Cell Cycle; C | 2016 |
The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Topics: Apoptosis; Benzimidazoles; Brain Neoplasms; Carbamates; Cell Differentiation; Cell Proliferation; Di | 2017 |
The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH.
Topics: Amidohydrolases; Animals; Benzamides; Brain; Brain Neoplasms; Carbamates; Enzyme Inhibitors; Ethanol | 2006 |
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur | 1986 |